Observational studyRheumatology international2021
Short-term outcomes in children recovered from multisystem inflammatory syndrome associated with SARS-CoV-2 infection.
Observational study in Rheumatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 6 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Post-MIS-C cardiovascular outcomes: a systematic review.European journal of pediatrics · 2026Pooled it
- Clinical presentation, diagnosis and management of multisystem inflammatory syndrome in children (MIS-C): a systematic review.BMJ paediatrics open · 2024Pooled it
- Robustness of reported postacute health outcomes in children with SARS-CoV-2 infection: a systematic review.Archives of disease in childhood · 2023Pooled it
- Prevalence and risk factor for long COVID in children and adolescents: A meta-analysis and systematic review.Journal of infection and public health · 2023Pooled it
- Short and Long-Term Wellbeing of Children following SARS-CoV-2 Infection: A Systematic Review.International journal of environmental research and public health · 2022Pooled it
- Multisystem inflammatory syndrome (MIS-C): a systematic review and meta-analysis of clinical characteristics, treatment, and outcomes.Jornal de pediatriaPooled it
- Two-year follow-up on multisystem inflammatory syndrome in children (MIS-c): findings from a tertiary paediatric hospital in Latvia.European journal of pediatrics · 2025Article
- RNAseq-based transcriptomics of treatment-naïve multi-inflammatory syndrome in children (MIS-C) demonstrates predominant activation of matrisome, innate and humoral immune pathways.Rheumatology international · 2024Article
- Elevated risk for psychiatric outcomes in pediatric patients with Multisystem Inflammatory Syndrome (MIS-C): A review of neuroinflammatory and psychosocial stressors.Brain, behavior, & immunity - health · 2024Review
- Outpatient Pediatric Cardiology Follow-Up of Patients with Multisystem Inflammatory Syndrome in Children (MIS-C): A Single-Institution, Medium-Term Follow-Up Study.Pediatric cardiology · 2024Article
- Short-term and medium-term clinical outcomes of multisystem inflammatory syndrome in children: a prospective observational cohort study.Italian journal of pediatrics · 2024Observational
- New-onset systemic vasculitis following SARS-CoV-2 infection and vaccination: the trigger, phenotype, and outcome.Clinical rheumatology · 2023Review
- Longitudinal Assessment of Cardiac Function Following Multisystem Inflammatory Syndrome in Children Associated with COVID-19.Pediatric cardiology · 2023Article
- Short- and mid-term outcomes of multisystem inflammatory syndrome in children: a longitudinal prospective single-center cohort study.Frontiers in pediatrics · 2023Article
- Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study.Rheumatology international · 2022Article
- Population-based study of multisystem inflammatory syndrome associated with COVID-19 found that 36% of children had persistent symptoms.Acta paediatrica (Oslo, Norway : 1992) · 2022Article
- Multisystem Inflammatory Syndrome and Autoimmune Diseases Following COVID-19: Molecular Mechanisms and Therapeutic Opportunities.Frontiers in molecular biosciences · 2022Review
- Outpatient monitoring of patients with multisystem inflammatory syndrome (MIS-C): A mini review.Frontiers in pediatrics · 2022Review
- COVID-19 in Early Life: Infants and Children Are Affected Too.Physiology (Bethesda, Md.) · 2021Review
- Post-COVID multisystem inflammatory syndrome in adults: a study from a tertiary care hospital in south India.The Indian journal of medical researchArticle
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multi-system inflammatory syndrome in children (MIS-C) associated with COVID-19 is a recently recognised potentially life-threatening entity. There is limited data on post-MIS-C sequelae. 21 children fulfilling the WHO criteria for MIS-C were included in our study. Data were collected at baseline and at 12-16 weeks post-discharge to look for any persistent sequelae mainly relating to the lungs or heart including coronary arteries. Fever was the most common presentation, found in 18 (85.7%) patients. All had a marked hyper-inflammatory state. Low ejection fraction (EF) was found in 10 (47.6%), but none had any coronary artery abnormality. All received corticosteroids, while 7 (33.3%) children required additional treatment with intravenous Immunoglobulins. 20 children improved while 1 left against medical advice. At discharge, 3 children had impaired left ventricular function. At median 15 weeks' follow-up, no persistent complications were found. EF had returned to normal and no coronary artery abnormalities were found during repeat echocardiography. Chest radiographs showed no fibrosis and all biochemical parameters had normalized. The children with MIS-C are extremely sick during the acute stage. Timely and adequate management led to full recovery without any sequelae at a median follow-up of 15 weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.